載入中
NASDAQConsumer DefensiveTobacco
最新資料
US$0.7244
−US$0.0872 · -10.74%
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
前收盤價
US$0.7244
−US$0.0872 · -10.74%
盤後
US$0.7401
+US$0.0157 · +2.17%
10月12日 下午6:30 ET
盤中時間採用ET。市場資料可能有所延遲。
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
日內區間
目前US$0.7244
52週區間
目前US$0.7244
盤中時間採用ET。市場資料可能有所延遲。
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
日內區間
目前US$0.7244
52週區間
目前US$0.7244
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 704.9萬 USD | 1187.8萬 USD | 3220.4萬 USD | 4050.1萬 USD | 3094.8萬 USD |
| 銷貨成本 | 1018.6萬 USD | 1427.8萬 USD | 4090萬 USD | 3865.4萬 USD | 2946.2萬 USD |
| 毛利 | −313.7萬 USD | −240萬 USD | −869.6萬 USD | 184.7萬 USD | 148.6萬 USD |
| 研究與開發 | 68.8萬 USD | 113.3萬 USD | 264.4萬 USD | 357.8萬 USD | 391.2萬 USD |
| 銷售、一般及管理費用 | 759.1萬 USD | 1028.7萬 USD | 3182.7萬 USD | 3223.1萬 USD | 2590.8萬 USD |
| 營業費用 | 827.9萬 USD | 1155萬 USD | 3623.5萬 USD | 3548.2萬 USD | 2989.8萬 USD |
| 利息收入 | 8.3萬 USD | 7.2萬 USD | 21.9萬 USD | 31.3萬 USD | 32.1萬 USD |
| 利息支出 | 145.5萬 USD | 209.4萬 USD | 936.6萬 USD | 5.5萬 USD | 5.8萬 USD |
| 折舊和攤銷 | 115.7萬 USD | 125.8萬 USD | 485.9萬 USD | 359.1萬 USD | 153.6萬 USD |
| 營業利益 | −1141.6萬 USD | −1395萬 USD | −4493.1萬 USD | −3363.5萬 USD | −2841.2萬 USD |
| 淨利 | −505.4萬 USD | −1516.4萬 USD | −1.41億 USD | −5980.1萬 USD | −3260.9萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$1,237.5
上漲空間 170731.03%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年6月12日 | 1:20 | — | — |
股票分割 | 2026年1月26日 | 1:15 | — | — |
股票分割 | 2025年6月20日 | 1:23 | — | — |
股票分割 | 2024年12月17日 | 1:135 | — | — |
股票分割 | 2024年4月2日 | 1:16 | — | — |
股票分割 | 2023年7月5日 | 1:15 | — | — |
已生效 2026年6月12日
1:20
已生效 2026年1月26日
1:15
已生效 2025年6月20日
1:23
已生效 2024年12月17日
1:135
已生效 2024年4月2日
1:16
已生效 2023年7月5日
1:15
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
